Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2013 1
2016 1
2017 3
2018 2
2019 2
2020 3
2021 2
2022 4
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: morton lt. Cancer Res. 2024 May 2;84(9):1534. doi: 10.1158/0008-5472.CAN-24-0718. Cancer Res. 2024. PMID: 38693893 No abstract available.
Breaking the performance ceiling for neoantigen immunogenicity prediction.
O'Brien H, Salm M, Morton LT, Szukszto M, O'Farrell F, Boulton C, Becker PD, Samuels Y, Swanton C, Mansour MR, Reker Hadrup S, Quezada SA. O'Brien H, et al. Among authors: morton lt. Nat Cancer. 2023 Dec;4(12):1618-1621. doi: 10.1038/s43018-023-00675-z. Nat Cancer. 2023. PMID: 38102360 No abstract available.
Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.
van Amerongen RA, Morton LT, Chaudhari UG, Remst DFG, Hagedoorn RS, van den Berg CW, Freund C, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: morton lt. Mol Ther Methods Clin Dev. 2023 Jan 20;28:249-261. doi: 10.1016/j.omtm.2023.01.005. eCollection 2023 Mar 9. Mol Ther Methods Clin Dev. 2023. PMID: 36816758 Free PMC article.
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: morton lt. Cancer Res. 2022 Mar 1;82(5):773-784. doi: 10.1158/0008-5472.CAN-21-2200. Cancer Res. 2022. PMID: 34965933
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: morton lt. Mol Ther. 2022 Feb 2;30(2):564-578. doi: 10.1016/j.ymthe.2021.08.010. Epub 2021 Aug 8. Mol Ther. 2022. PMID: 34371177 Free PMC article.
23 results